Skip to Content

Hydroxyprogesterone Pregnancy and Breastfeeding Warnings

Hydroxyprogesterone is also known as: Delalutin, Delta-Lutin, Duralutin, Hylutin, Hyprogesterone, Makena, Prodrox

Hydroxyprogesterone Pregnancy Warnings

Hydroxyprogesterone has been assigned to pregnancy category B by the FDA. There are no adequate and well controlled studies of hydroxyprogesterone use in women during the first trimester of pregnancy. Data from a vehicle (placebo)-controlled clinical trial of 310 pregnant women who received hydroxyprogesterone at weekly doses of 250 mg by intramuscular injection in their second and third trimesters, as well as long-term (2 to 5 years) follow-up safety data on 194 of their infants, did not did not demonstrate any teratogenic risks to infants from in utero exposure. Hydroxyprogesterone is only recommended for use during pregnancy when benefit outweighs risk.

See references

Hydroxyprogesterone Breastfeeding Warnings

Detectable amounts of progestins have been identified in the milk of mothers receiving progestin treatment. Many studies have found no adverse effects of progestins on breastfeeding performance, or on the health, growth, or development of the infant. There is no indication for hydroxyprogesterone after delivery. Discontinue hydroxyprogesterone at 37 weeks of gestation or upon delivery.

See references

References for pregnancy information

  1. "Product Information. Makena (hydroxyprogesterone)." Ther-Rx Corporation, Bridgeton, MO.

References for breastfeeding information

  1. "Product Information. Makena (hydroxyprogesterone)." Ther-Rx Corporation, Bridgeton, MO.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.